MCID: VTR008
MIFTS: 34

Vitreoretinal Degeneration

Categories: Rare diseases, Eye diseases

Aliases & Classifications for Vitreoretinal Degeneration

MalaCards integrated aliases for Vitreoretinal Degeneration:

Name: Vitreoretinal Degeneration 50 29 69

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


Summaries for Vitreoretinal Degeneration

MalaCards based summary : Vitreoretinal Degeneration is related to stickler syndrome and wagner syndrome. An important gene associated with Vitreoretinal Degeneration is KCNJ13 (Potassium Voltage-Gated Channel Subfamily J Member 13), and among its related pathways/superpathways are ERK Signaling and Integrin Pathway. The drugs Ranibizumab and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include eye and endothelial, and related phenotypes are craniofacial and hearing/vestibular/ear

Related Diseases for Vitreoretinal Degeneration

Diseases in the Vitreoretinal Degeneration family:

Secondary Vitreoretinal Degeneration

Diseases related to Vitreoretinal Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 stickler syndrome 29.5 COL2A1 COL9A2
2 wagner syndrome 27.9 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2 KCNJ13
3 snowflake vitreoretinal degeneration 12.5
4 myopia, high, with cataract and vitreoretinal degeneration 12.3
5 secondary vitreoretinal degeneration 12.0
6 wagner syndrome 1 11.6
7 knobloch syndrome, type 1 11.0
8 stickler syndrome, type v 10.9
9 stickler syndrome, type i 10.9
10 hypersensitivity vasculitis 10.1 COL2A1 KCNJ13
11 retinitis 10.0
12 retinal detachment 10.0
13 bone structure disease 9.9 COL2A1 COL9A2
14 chromosomal disease 9.8 COL2A1 COL9A2
15 dysmorphism-short stature-deafness-disorder of sex development syndrome 9.8 COL11A1 COL9A2
16 alport syndrome 9.7
17 ectropion 9.7
18 night blindness 9.7
19 neuropathy 9.7
20 chorioretinitis 9.7
21 cleft lip 9.7
22 knobloch syndrome 9.7
23 skeletal dysplasias 9.7
24 skeletal dysplasia 9.7
25 congenital ectropion uveae 9.7
26 marshall syndrome 9.7 COL11A1 COL2A1
27 craniodiaphyseal dysplasia 9.7 COL11A1 COL2A1
28 laryngomalacia 9.6 COL11A1 COL2A1
29 smed strudwick type 9.6 COL11A1 COL2A1
30 ischemic bone disease 9.6 COL2A1 COL9A2
31 acromesomelic dysplasia 9.6 COL11A1 COL2A1
32 achondrogenesis, type ii or hypochondrogenesis 9.6 COL11A1 COL2A1
33 epileptic encephalopathy, early infantile, 7 9.6 COL11A1 COL9A2
34 sulfite oxidase deficiency 9.4 COL11A1 COL2A1
35 myasthenic syndrome, congenital, 2a, slow-channel 9.4 COL11A1 COL2A1
36 plantar nerve lesion 9.4 COL11A1 COL2A1 KCNJ13
37 ureter cancer 9.4 COL11A1 COL2A1 KCNJ13
38 adult-onset still's disease 9.4 COL11A1 COL2A1 KCNJ13
39 charcot-marie-tooth disease type 5 9.2 COL11A1 COL2A1 COL9A2
40 intermediate uveitis 9.2 COL11A1 COL2A1 COL9A2
41 paget's disease of bone 9.1 COL11A1 COL2A1
42 testicular granulosa cell tumor 8.9 COL11A1 COL18A1 COL2A1 KCNJ13
43 moyamoya disease 8.9 COL11A1 COL2A1 COL4A3 KCNJ13
44 clubfoot 8.4 COL11A1 COL18A1 COL2A1 COL9A2 P3H2

Graphical network of the top 20 diseases related to Vitreoretinal Degeneration:



Diseases related to Vitreoretinal Degeneration

Symptoms & Phenotypes for Vitreoretinal Degeneration

MGI Mouse Phenotypes related to Vitreoretinal Degeneration:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.56 COL11A1 COL18A1 COL2A1 KCNJ13
2 hearing/vestibular/ear MP:0005377 9.46 COL11A1 COL2A1 COL4A3 COL9A2
3 limbs/digits/tail MP:0005371 9.26 COL11A1 COL2A1 COL4A3 COL9A2
4 skeleton MP:0005390 9.02 COL11A1 COL18A1 COL2A1 COL9A2 KCNJ13

Drugs & Therapeutics for Vitreoretinal Degeneration

Drugs for Vitreoretinal Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
4
Temazepam Approved Phase 4 846-50-4 5391
5
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2 129497-78-5
6 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
7 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
8 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
9 Hormones Phase 4,Phase 2,Phase 3,Phase 1
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
11 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
12 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
13 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Anesthetics Phase 4
15 Anesthetics, Local Phase 4
16 Central Nervous System Depressants Phase 4
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1
19 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Phase 1
20 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Phase 1
21 Anti-Anxiety Agents Phase 4
22 GABA Agents Phase 4
23 GABA Modulators Phase 4
24 Hypnotics and Sedatives Phase 4
25 Neurotransmitter Agents Phase 4,Phase 2
26 Psychotropic Drugs Phase 4
27 Tranquilizing Agents Phase 4
28 Dermatologic Agents Phase 4,Phase 3
29 Photosensitizing Agents Phase 4,Phase 3
30
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1 216974-75-3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
32
Ephedrine Approved Phase 2, Phase 3 299-42-3 9294
33
Pseudoephedrine Approved Phase 2, Phase 3 90-82-4 7028
34
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
35 Antiemetics Phase 2, Phase 3
36 Antineoplastic Agents, Hormonal Phase 2, Phase 3
37 Autonomic Agents Phase 2, Phase 3
38 BB 1101 Phase 2, Phase 3
39 Dexamethasone acetate Phase 2, Phase 3 1177-87-3
40 Gastrointestinal Agents Phase 2, Phase 3
41 HIV Protease Inhibitors Phase 2, Phase 3
42 Nasal Decongestants Phase 2, Phase 3
43 Ophthalmic Solutions Phase 2, Phase 3
44 Pharmaceutical Solutions Phase 2, Phase 3
45
protease inhibitors Phase 2, Phase 3
46 Respiratory System Agents Phase 2, Phase 3
47 Tetrahydrozoline Phase 2, Phase 3
48 Vasoconstrictor Agents Phase 2, Phase 3
49 Antibodies Phase 3,Phase 2
50 Immunoglobulin Fab Fragments Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 63)

id Name Status NCT ID Phase Drugs
1 A Long-Term Monitoring Study of the IMT-002 Patients Completed NCT00976235 Phase 4
2 Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
3 20- Versus 23- Gauge System for Pars Plana Vitrectomy Completed NCT00411970 Phase 4
4 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Recruiting NCT03097068 Phase 4 Lucentis
5 Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab Not yet recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
6 Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Not yet recruiting NCT03056079 Phase 4 Intravitreal aflibercept
7 Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration Terminated NCT00423189 Phase 4 Ranibizumab (Lucentis);0.5mg ranibizumab
8 A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration Unknown status NCT00454389 Phase 3 ranibizumab
9 Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema Unknown status NCT01523314 Phase 2, Phase 3 dexamethasone - Cyclodextrin eye drops
10 Bevacizumab Versus Ranibizumab for Diabetic Retinopathy Completed NCT00545870 Phase 3 bevacizumab;Ranibizumab
11 A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration Completed NCT00061594 Phase 3 rhuFab V2 (ranibizumab)
12 Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Completed NCT00593450 Phase 3 ranibizumab;bevacizumab
13 Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration Completed NCT00100009 Phase 3 TAC-PF;Triamcinolone Acetonide
14 Combined Triple Therapy in Diabetic Retinopathy (DRP) Completed NCT00806169 Phase 3 triamcinolone and bevacizumab
15 Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) Recruiting NCT02745119 Phase 3 Lampalizumab
16 Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) Recruiting NCT01782989 Phase 2, Phase 3 ORACEA®;Placebo
17 Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration Active, not recruiting NCT02462486 Phase 3 abicipar pegol;ranibizumab
18 A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Active, not recruiting NCT02247531 Phase 3 Lampalizumab
19 A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Active, not recruiting NCT02247479 Phase 3 Lampalizumab
20 A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration Active, not recruiting NCT02462928 Phase 3 abicipar pegol;ranibizumab
21 Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis Suspended NCT00460967 Phase 3
22 Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD Terminated NCT00499590 Phase 3 bevasiranib;ranibizumab
23 Combination Therapy for Age-Related Macular Degeneration. Completed NCT00376701 Phase 2 Avastin (Bevacizumab);Bevacizumab;Bevacizumab;Bevacizumab
24 Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration Completed NCT01926977 Phase 1, Phase 2 Ranibizumab 0.5mg;Aflibercept 2.0mg
25 Lucentis to Treat Pigment Epithelial Detachment Completed NCT00841581 Phase 2 Ranibizumab
26 Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration Completed NCT00259753 Phase 2 Bevasiranib
27 A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration Completed NCT00447954 Phase 2 NT-501 implant;NT-501 implant
28 Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD) Completed NCT00320788 Phase 2
29 Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy Completed NCT01472510 Phase 2 Ranibizumab;Ranibizumab
30 Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion Completed NCT00913744 Phase 2 Ocriplasmin;Sham injection
31 Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema Completed NCT00440609 Phase 1, Phase 2 ranibizumab
32 A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy Completed NCT02288559 Phase 2 Lampalizumab
33 Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema Completed NCT02363621 Phase 2 Ranibizumab 0.3 mg;Aflibercept 2.0 mg
34 IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD Recruiting NCT02462889 Phase 2 Intravitreal aflibercept injection;Placebo
35 Study of the Efficacy and Safety of the Ranibizumab Port Delivery System (RPDS) for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) (LADDER) Recruiting NCT02510794 Phase 2 Ranibizumab
36 Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Recruiting NCT02402660 Phase 2 ALK-001;Placebo
37 Study to Evaluate RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD) Active, not recruiting NCT03038880 Phase 2 RO6867461;Ranibizumab
38 A Proof-of-Concept Study of RO6867461 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Active, not recruiting NCT02484690 Phase 2 RO6867461;Ranibizumab
39 A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration Active, not recruiting NCT02087085 Phase 2 400 µg Brimonidine Implant
40 Argus® II Retinal Stimulation System Feasibility Protocol Active, not recruiting NCT00407602 Phase 2
41 Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration Terminated NCT01577381 Phase 2
42 Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD Terminated NCT00509548 Phase 2 TG100801
43 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment Unknown status NCT00548197 Phase 1 Bevacizumab
44 Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration Unknown status NCT00767949 Phase 1
45 A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD Completed NCT00536016 Phase 1 JSM6427
46 Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema Completed NCT00915837 Phase 1 triamcinolone acetonide;triamcinolone acetonide
47 Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Recruiting NCT03295877 Phase 1 RO7171009
48 Evaluation of TeleOphthalmology in AMD-TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes Unknown status NCT01581606
49 Triple Therapy for Diffuse Diabetic Macular Edema Unknown status NCT01218750
50 Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration Completed NCT01473251 Avastin;Avastin;Lucentis

Search NIH Clinical Center for Vitreoretinal Degeneration

Genetic Tests for Vitreoretinal Degeneration

Genetic tests related to Vitreoretinal Degeneration:

id Genetic test Affiliating Genes
1 Vitreoretinal Degeneration 29

Anatomical Context for Vitreoretinal Degeneration

MalaCards organs/tissues related to Vitreoretinal Degeneration:

39
Eye, Endothelial

Publications for Vitreoretinal Degeneration

Articles related to Vitreoretinal Degeneration:

(show all 32)
id Title Authors Year
1
Snowflake vitreoretinal degeneration (SVD) mutation R162W provides new insights into Kir7.1 ion channel structure and function. ( 23977131 )
2013
2
Mutations in KCNJ13 cause autosomal-dominant snowflake vitreoretinal degeneration. ( 18179896 )
2008
3
Genetic linkage of snowflake vitreoretinal degeneration to chromosome 2q36. ( 15557460 )
2004
4
Vitreoretinal degeneration complicated by retinal detachment in alport syndrome. ( 12652248 )
2003
5
Snowflake vitreoretinal degeneration: follow-up of the original family. ( 14644728 )
2003
6
Goldmann-Favre vitreoretinal degeneration. ( 12747653 )
2003
7
A frame shift mutation in a tissue-specific alternatively spliced exon of collagen 2A1 in Wagner's vitreoretinal degeneration. ( 12208278 )
2002
8
A frame shift mutation in a tissue-specific alternatively spliced exon of collagen 2A1 in Wagner's vitreoretinal degeneration. ( 11812423 )
2002
9
Stickler syndrome and vitreoretinal degeneration: correlation between locus mutation and vitreous phenotype. Apropos of a case. ( 11450497 )
2001
10
Wagner vitreoretinal degeneration with genetic linkage refinement on chromosome 5q13-q14. ( 10333105 )
1999
11
Joint laxity, vitreoretinal degeneration, facial abnormalities, and generalized skeletal alterations: a new syndrome? ( 9747034 )
1998
12
Primary congenital ectropion uveae associated with vitreoretinal degeneration. ( 9438589 )
1998
13
Peripheral neuropathy: an unrecognized feature of hereditary vitreoretinal degeneration? ( 8719653 )
1996
14
Wagner vitreoretinal degeneration. Follow-up of the original pedigree. ( 9098284 )
1995
15
Congenital scalp defects and vitreoretinal degeneration: redefining the Knobloch syndrome. ( 8484411 )
1993
16
Autosomal dominant juvenile vitreoretinal degeneration and retinal detachment. ( 3721711 )
1986
17
Juvenile vitreoretinal degeneration and retinal detachment. ( 3002098 )
1985
18
Prophylactic laser photocoagulation in hereditary snowflake vitreoretinal degeneration. A family report. ( 6626003 )
1983
19
Clinical variability in vitreoretinal degeneration. ( 6873954 )
1983
20
Hereditary snowflake vitreoretinal degeneration. ( 7171777 )
1982
21
Vitreoretinal degeneration in facial clefting syndrome. ( 7171778 )
1982
22
Wagner's vitreoretinal degeneration with generalized epiphyseal dysplasia. ( 7136558 )
1982
23
Vitreoretinal degeneration in spondyloepiphyseal dysplasia congenita. ( 6807266 )
1982
24
Chorioretinal dysplasia in young subjects with Wagner's hereditary vitreoretinal degeneration. ( 7228506 )
1981
25
Wagner's vitreoretinal degeneration. ( 7283320 )
1980
26
Wagner's hereditary vitreoretinal degeneration. ( 7387542 )
1980
27
Hereditary vitreoretinal degeneration, cleft lip and palate, deafness, and skeletal dysplasia. ( 6966133 )
1980
28
Vitrectomy and Wagner's vitreoretinal degeneration. ( 434083 )
1979
29
Vitrectomy and Wagner's vitreoretinal degeneration. ( 707593 )
1978
30
Snowflake degeneration in hereditary vitreoretinal degeneration. ( 4812083 )
1974
31
Wagner's hereditary vitreoretinal degeneration and retinal detachment. ( 4691317 )
1973
32
Hereditary vitreoretinal degeneration and night blindness. ( 5305106 )
1969

Variations for Vitreoretinal Degeneration

Expression for Vitreoretinal Degeneration

Search GEO for disease gene expression data for Vitreoretinal Degeneration.

Pathways for Vitreoretinal Degeneration

Pathways related to Vitreoretinal Degeneration according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2
2
Show member pathways
12.9 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2
3
Show member pathways
12.55 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2
4
Show member pathways
12.39 COL11A1 COL2A1 COL4A3 COL9A2
5
Show member pathways
12.09 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2 P3H2
6
Show member pathways
11.89 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2 KCNJ13
7
Show member pathways
11.63 COL18A1 COL2A1 COL4A3 COL9A2
8 11.22 COL2A1 COL4A3
9 10.97 COL4A3 COL9A2

GO Terms for Vitreoretinal Degeneration

Cellular components related to Vitreoretinal Degeneration according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2
2 proteinaceous extracellular matrix GO:0005578 9.65 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2
3 extracellular matrix GO:0031012 9.5 COL11A1 COL18A1 COL2A1
4 basement membrane GO:0005604 9.46 COL18A1 COL2A1 COL4A3 P3H2
5 endoplasmic reticulum lumen GO:0005788 9.43 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2 P3H2
6 collagen trimer GO:0005581 9.02 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2

Biological processes related to Vitreoretinal Degeneration according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.69 COL18A1 COL4A3 P3H2
2 visual perception GO:0007601 9.54 COL11A1 COL18A1 COL2A1
3 ossification GO:0001503 9.52 COL11A1 COL2A1
4 cartilage development GO:0051216 9.49 COL11A1 COL2A1
5 inner ear morphogenesis GO:0042472 9.48 COL11A1 COL2A1
6 heart morphogenesis GO:0003007 9.46 COL11A1 COL2A1
7 skeletal system morphogenesis GO:0048705 9.43 COL11A1 COL2A1
8 sensory perception of sound GO:0007605 9.43 COL11A1 COL2A1 COL4A3
9 collagen fibril organization GO:0030199 9.4 COL11A1 COL2A1
10 cartilage condensation GO:0001502 9.32 COL11A1 COL2A1
11 collagen catabolic process GO:0030574 9.26 COL11A1 COL18A1 COL2A1 COL4A3
12 proteoglycan metabolic process GO:0006029 9.16 COL11A1 COL2A1
13 extracellular matrix organization GO:0030198 9.02 COL11A1 COL18A1 COL2A1 COL4A3 COL9A2

Molecular functions related to Vitreoretinal Degeneration according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent conferring tensile strength GO:0030020 8.96 COL2A1 COL9A2
2 extracellular matrix structural constituent GO:0005201 8.8 COL11A1 COL2A1 COL4A3

Sources for Vitreoretinal Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....